• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Bruce A. Chabner, MD


  • Chabner BA.Approval after phase I: ceritinib runs the three-minute mile.Oncologist. 2014 Jun;19(6):577-8.
  • Gainor JF, Longo DL, Chabner BA.Pharmacodynamic biomarkers: falling short of the mark?.Clin Cancer Res. 2014 May 15;20(10):2587-94.
  • Chabner BA.Effective double whammy targets DNA synthesis in leukemia.J Exp Med. 2014 Mar 10;211(3):384.
  • Chabner BA, Efstathiou J, Dryden-Peterson S, .Cancer in Botswana: the second wave of AIDS in Sub-Saharan Africa.Oncologist. 2013;18(7):777-8.
  • Fojo AT, Bates SE, Chabner BA.Clinical trial results: Sharing results, speeding discoveries.Oncologist. 2013;18(7):779.
  • Chabner BA, Ellisen LW, Iafrate AJ.Personalized medicine: hype or reality.Oncologist. 2013 Jun;18(6):640-3.
  • Percac-Lima S, Benner CS, Lui R, Aldrich LS, Oo SA, Regan N, Chabner BA.The impact of a culturally tailored patient navigator program on cervical cancer prevention in latina women.J Womens Health (Larchmt). 2013 May;22(5):426-31.
  • Cote GM, Sawyer DB, Chabner BA.ERBB2 inhibition and heart failure.N Engl J Med. 2012 Nov 29;367(22):2150-3.
  • Chabner BA.That old devil moon.Oncologist. 2012;17(11):1349-50.
  • Raj A, Ko N, Battaglia TA, Chabner BA, Moy B.Patient navigation for underserved patients diagnosed with breast cancer.Oncologist. 2012;17(8):1027-31.
  • Chabner BA.Early accelerated approval for highly targeted cancer drugs.N Engl J Med. 2011 Mar 24;364(12):1087-9.
  • Murphy JP, Chabner BA.Reflections on the knife edge.Oncologist. 2011;16(2):257-9.
  • Chabner BA.New results will change the paradigm for phase I trials and drug approval.Oncologist. 2010;15(10):1023-5.
  • Donelan K, Mailhot JR, Dutwin D, Barnicle K, Oo SA, Hobrecker K, Percac-Lima S, Chabner BA.Patient Perspectives of Clinical Care and Patient Navigation in Follow-up of Abnormal Mammography.J Gen Intern Med. 2010 Jul 7.
  • Chabner BA.About Eli.Oncologist. 2010;15(4):329-31.
  • Chabner BA.Academia-pharma intersect: providing a broader perspective on drug development synergies between academia and industry.Oncologist. 2010;15(1):1-2.
  • Chong CR, Chabner BA.Mysterious metformin.Oncologist. 2009 Dec;14(12):1178-81.
  • Lane AA, Chabner BA.Histone deacetylase inhibitors in cancer therapy.J Clin Oncol. 2009 Nov 10;27(32):5459-68. Review.
  • Donelan K,Hobrecker K,Schapira L,Mailhot JR,Goulart BH,Chabner BA.Medical interpreter knowledge of cancer and cancer clinical trials.Cancer. 2009 Jul 15;115(14):3283-92.
  • Chabner BA.Obituary.Cancer Sci. 2009 Apr;100(4):565-6.
  • Chabner BA.Ghost writers in the sky.Oncologist. 2009 Mar;14(3):199-200.
  • Chabner BA.The National Cancer Institute and its Director: worthy of our full support.Oncologist. 2009 Feb;14(2):108-9.
  • Schapira L,Gordon-Rowe L,Martignetti R,Washington D,Bartholomay M,Greenberg D,Lathan C,LaFrancesca J,Lynch T,Chabner B.Racism in the chemotherapy infusion unit: a nurse's story.Oncologist. 2008 Nov;13(11):1177-80.
  • Chabner BA.Dr. Joseph R. Bertino: a reflection.Oncologist. 2008 Oct;13(10):1034-5.
  • Chabner BA.Preserving the sacred bond: an audit must be performed.Oncologist. 2008 Sep;13(9):922.
  • Curt GA,Chabner BA.One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis?.Oncologist. 2008 Sep;13(9):923-4.
  • Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE.Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers.J Clin Oncol. 2008 Jun 1;26(16):2717-24.
  • Chabner BA.Smoke, then Fire: Lung Cancer Screening Studies Under Further Scrutiny.Oncologist. 2008 Apr;13(4):348-9.
  • Chabner BA.Conflict of interest: in the eye of the beholder?.Oncologist. 2008 Mar;13(3):212-3.
  • Chabner B.Advances and challenges in the use of biomarkers in clinical trials.Clin Adv Hematol Oncol. 2008 Jan;6(1):42-3. Review.
  • Novina CD, Chabner BA.RNA-Directed Therapy: The Next Step in the miRNA Revolution.Oncologist. 2008 Jan;13(1):1-3.
  • Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA.Trends in the use and role of biomarkers in phase I oncology trials.Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6719-26. Review.
  • Chabner BA, Ratain MJ.Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".Clin Cancer Res. 2007 Nov 1;13(21):6540.
  • Kwak EL, Clark JW, Chabner B.Targeted agents: the rules of combination.Clin Cancer Res. 2007 Sep 15;13(18):5232-7. Review.
  • Chabner BA.Orange alert for oncologists.Oncologist. 2007 Aug;12(8):902-3.
  • Chabner B.Phase II cancer trials: out of control?.Clin Cancer Res. 2007 Apr 15;13(8):2307-8.
  • Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJ.Teams: communication in multidisciplinary care.Oncologist. 2006 May;11(5):520-6. Review.
  • Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ.Direct-to-consumer advertising in oncology.Oncologist. 2006 Feb;11(2):217-26.
  • Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ.Laughter: the best medicine?.Oncologist. 2005 Sep;10(8):651-60.
  • Chabner BA, Murphy MJ.Breast cancer: a tale of two centuries: with implications for understanding cancer metastasis and cancer stem cell biology.Oncologist. 2005 Jun-Jul;10(6):369.
  • Wolpin BM, Chabner BA, Lynch TJ, Penson RT.Learning to cope: how far is too close?.Oncologist. 2005 Jun-Jul;10(6):449-56.
  • Penson RT, Partridge RA, Shah MA, Giansiracusa D, Chabner BA, Lynch TJ.Fear of death.Oncologist. 2005 Feb;10(2):160-9.
  • Chabner BA, Roberts TG.Timeline: Chemotherapy and the war on cancer.Nat Rev Cancer. 2005 Jan;5(1):65-72.
  • Roberts TG, Chabner BA.Beyond fast track for drug approvals.N Engl J Med. 2004 Jul 29;351(5):501-5.
  • Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV.Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.Clin Cancer Res. 2004 Jun 1;10(11):3927-33.
  • Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ.Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.Clin Cancer Res. 2004 Jun 1;10(11):3885-96.
  • Penson RT, Talsania SH, Chabner BA, Lynch TJ.Help me help you: support groups in cancer therapy.Oncologist. 2004;9(2):217-25.
  • Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG.Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.Clin Colorectal Cancer. 2004 Feb;3(4):225-34.
  • Dias L, Chabner BA, Lynch TJ, Penson RT.Breaking bad news: a patient's perspective.Oncologist. 2003;8(6):587-96.
  • Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ.The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless.Oncologist. 2003;8(5):488-95.
  • Roberts TG, Lynch TJ, Chabner BA.The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.J Clin Oncol. 2003 Oct 1;21(19):3683-95.
  • Brugarolas J, Clark JW, Chabner B.Using "rationally designed drugs" rationally.Lancet. 2003 May 24;361(9371):1758-9.
  • Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch TJ, Penson RT.Living as a cancer surpriser: a doctor tells his story.Oncologist. 2003;8(1):108-22.
  • Penson RT, Benson RC, Parles K, Chabner BA, Lynch TJ.Virtual connections: Internet health care.Oncologist. 2002;7(6):555-68.
  • Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT.Faith, identity, and leukemia: when blood products are not an option.Oncologist. 2002;7(4):371-80.
  • Penson RT, Green KM, Chabner BA, Lynch TJ.When does the responsibility of our care end: bereavement.Oncologist. 2002;7(3):251-8.
  • Roberts TG, Lynch TJ, Chabner BA.Choosing chemotherapy for lung cancer based on cost: not yet.Oncologist. 2002;7(3):177-8.
  • Penson RT, Rauch PK, McAfee SL, Cashavelly BJ, Clair-Hayes K, Dahlin C, Green KM, Chabner BA, Lynch TJ.Between parent and child: negotiating cancer treatment in adolescents.Oncologist. 2002;7(2):154-62.
  • Chabner BA, Wittes R, Balis F.Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.Blood. 2002 Apr 15;99(8):2685-93.
  • Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F.Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.Blood. 2002 Apr 15;99(8):2685-93.
  • Penson RT, Castro CM, Seiden MV, Chabner BA, Lynch TJ.Complementary, alternative, integrative, or unconventional medicine?.Oncologist. 2001;6(5):463-73.
  • Penson RT, Seiden MV, Chabner BA, Lynch TJ.Caring for colleagues.Oncologist. 2001;6(2):197-204.
  • Penson RT, Svendsen SS, Chabner BA, Lynch TJ, Levinson W.Medical mistakes: a workshop on personal perspectives.Oncologist. 2001;6(1):92-9.
  • Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH.Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.J Clin Oncol. 2000 Nov 1;18(21):3633-42.
  • Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ.Sexuality and cancer: conversation comfort zone.Oncologist. 2000;5(4):336-44.
  • Penson RT, Seiden MV, Shannon KM, Lubratovich ML, Roche M, Chabner BA, Lynch TJ.Communicating genetic risk: pros, cons, and counsel.Oncologist. 2000;5(2):152-61.
  • Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ.Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.Oncologist. 2000;5(1):53-62.
  • Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE.Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.J Clin Oncol. 1995 Aug;13(8):1985-94.
  • Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J.Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.J Clin Oncol. 1995 Aug;13(8):1995-2004.
  • Saikawa Y, Knight CB, Saikawa T, Page ST, Chabner BA, Elwood PC.Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells.J Biol Chem. 1993 Mar 5;268(7):5293-301.